{"id":745707,"date":"2018-06-12T15:06:00","date_gmt":"2018-06-12T15:06:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/"},"modified":"2025-11-07T01:27:14","modified_gmt":"2025-11-07T06:27:14","slug":"fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/","title":{"rendered":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA Now First Anti-PD-1 Therapy Approved for Patients with        Advanced Cervical Cancer and Disease Progression on or After Chemotherapy     <\/p>\n<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved KEYTRUDA<sup>\u00ae<\/sup>, the company\u2019s anti-PD-1 therapy, for the<br \/>\n      treatment of patients with recurrent or metastatic cervical cancer with<br \/>\n      disease progression on or after chemotherapy whose tumors express PD-L1<br \/>\n      [Combined Positive Score (CPS) \u22651] as determined by an FDA-approved test.<b><br \/>\n      <\/b>This indication is approved under the FDA\u2019s accelerated approval<br \/>\n      regulations based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      \u201cKEYTRUDA is now the first anti-PD-1 therapy approved for the treatment<br \/>\n      of advanced cervical cancer, providing an important new second-line<br \/>\n      option for certain patients with this disease,\u201d said Dr. Roy Baynes,<br \/>\n      senior vice president and head of global clinical development, chief<br \/>\n      medical officer, Merck Research Laboratories. \u201cThis approval also marks<br \/>\n      the first indication for KEYTRUDA in a gynecologic cancer and reflects<br \/>\n      our ongoing commitment to bring forward innovative treatment options<br \/>\n      across a broad range of cancers, including cancers that<br \/>\n      disproportionately affect women.\u201d\n    <\/p>\n<p>\n      Immune-mediated adverse reactions occurred with KEYTRUDA, including<br \/>\n      pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe<br \/>\n      skin reactions, and solid organ transplant rejection. Based on the<br \/>\n      severity of the adverse reaction, KEYTRUDA should be withheld or<br \/>\n      discontinued and corticosteroids administered if appropriate. KEYTRUDA<br \/>\n      can also cause severe or life-threatening infusion-related reactions.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions;<br \/>\n      for Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA. Based on its mechanism of action, KEYTRUDA can cause fetal<br \/>\n      harm when administered to a pregnant woman. Female patients of<br \/>\n      reproductive potential should be advised of the potential hazard to a<br \/>\n      fetus. For more information, see \u201cSelected Important Safety Information\u201d<br \/>\n      below.\n    <\/p>\n<p>\n      &#8220;Even with the many advances observed across gynecologic cancers, new<br \/>\n      treatment options have been lacking for previously treated patients with<br \/>\n      advanced cervical cancer,\u201d said Dr. Bradley Monk, oncologist with<br \/>\n      Arizona Oncology, medical director of US Oncology Research Gynecology<br \/>\n      Program and professor of obstetrics and gynecology at University of<br \/>\n      Arizona\u2019s College of Medicine and Creighton University School of<br \/>\n      Medicine. \u201cThe approval of KEYTRUDA in this indication is important news<br \/>\n      \u2013 and as an oncologist, it is exciting to see a much needed option made<br \/>\n      available to these patients.\u201d\n    <\/p>\n<p>\n      \u201cThis approval is welcome news for patients, who now have another option<br \/>\n      in their fight against this serious disease,\u201d said Tamika Felder,<br \/>\n      founder and chief visionary officer, Cervivor.\n    <\/p>\n<p>\n      <b>Data Supporting the Approval<\/b>\n    <\/p>\n<p>\n      The efficacy of KEYTRUDA was investigated in 98 patients with recurrent<br \/>\n      or metastatic cervical cancer enrolled in a single cohort (Cohort E) in<br \/>\n      study KEYNOTE-158, a multi-center, non-randomized, open-label,<br \/>\n      multi-cohort trial. The trial excluded patients with autoimmune disease<br \/>\n      or a medical condition that required immunosuppression. Patients were<br \/>\n      treated with KEYTRUDA intravenously at a dose of 200 mg every three<br \/>\n      weeks until unacceptable toxicity or documented disease progression.<br \/>\n      Patients with initial radiographic disease progression could receive<br \/>\n      additional doses of treatment during confirmation of progression unless<br \/>\n      disease progression was symptomatic, was rapidly progressive, required<br \/>\n      urgent intervention, or occurred with a decline in performance status.<br \/>\n      Patients without disease progression could be treated for up to 24<br \/>\n      months. Assessment of tumor status was performed every nine weeks for<br \/>\n      the first 12 months, and every 12 weeks thereafter. The major efficacy<br \/>\n      outcome measures were objective response rate (ORR) according to<br \/>\n      Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed<br \/>\n      by blinded independent central review, and duration of response (DOR).\n    <\/p>\n<p>\n      Among the 98 patients in Cohort E, 77 (79%) had tumors that expressed<br \/>\n      PD-L1 with a CPS \u22651 and received at least one line of chemotherapy in<br \/>\n      the metastatic setting. PD-L1 status was determined using the PD-L1 IHC<br \/>\n      22C3 pharmDx Kit. The baseline characteristics of these 77 patients<br \/>\n      were: median age was 45 years (range, 27 to 75 years); 81 percent were<br \/>\n      White, 14 percent Asian, and three percent Black; ECOG PS was 0 (32%) or<br \/>\n      1 (68%); 92 percent had squamous cell carcinoma, six percent<br \/>\n      adenocarcinoma, and one percent adenosquamous histology; 95 percent had<br \/>\n      M1 disease and five percent had recurrent disease; 35 percent had one<br \/>\n      and 65 percent had two or more prior lines of therapy in the recurrent<br \/>\n      or metastatic setting.\n    <\/p>\n<p>\n      For the 77 patients whose tumors expressed PD-L1 with a CPS \u22651, the ORR<br \/>\n      was 14.3 percent (95% CI, 7.4-24.1), with a complete response rate of<br \/>\n      2.6 percent and partial response rate of 11.7 percent. Among the 11<br \/>\n      responding patients, median DOR was not yet reached (range, 4.1 to 18.6+<br \/>\n      months) and 91 percent experienced a duration of response of six months<br \/>\n      or longer. The median follow-up time was 11.7 months (range, 0.6 to 22.7<br \/>\n      months). No responses were observed in patients whose tumors did not<br \/>\n      have PD-L1 expression (CPS&lt;1).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in eight percent of<br \/>\n      98 patients (in Cohort E) enrolled with recurrent or metastatic cervical<br \/>\n      cancer. Serious adverse reactions occurred in 39 percent of patients<br \/>\n      receiving KEYTRUDA. The most frequent serious adverse reactions reported<br \/>\n      included anemia (7%), fistula, hemorrhage and infections [except urinary<br \/>\n      tract infections] (4.1% each). The most common adverse reactions<br \/>\n      (occurring in \u226520% of patients) were fatigue (43%), musculoskeletal pain<br \/>\n      (27%), diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body&#8217;s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry&#8217;s largest immuno-oncology clinical research<br \/>\n      program, which currently involves more than 750 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient&#8217;s likelihood of benefiting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae <\/b><br \/>\n<\/sup><br \/>\n<b>(pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is 200 mg every three weeks<br \/>\n      until disease progression, unacceptable toxicity or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA.<br \/>\n      While immune-mediated adverse reactions usually occur during treatment<br \/>\n      with PD-1\/PD-L1 blocking antibodies, they may occur after<br \/>\n      discontinuation of treatment. For suspected immune-mediated adverse<br \/>\n      reactions, ensure adequate evaluation to confirm etiology or exclude<br \/>\n      other causes. Based on the severity of the adverse reaction, withhold<br \/>\n      KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including cHL, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after treatment with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 developed<br \/>\n      graft-versus-host disease (GVHD) (one fatal case) and 2 developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning (one fatal case). Cases of fatal hyperacute GVHD after<br \/>\n      allogeneic HSCT have also been reported in patients with lymphoma who<br \/>\n      received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      Follow patients closely for early evidence of transplant-related<br \/>\n      complications such as hyperacute GVHD, Grade 3 to 4 acute GVHD,<br \/>\n      steroid-requiring febrile syndrome, hepatic VOD, and other<br \/>\n      immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients (in Cohort E) with recurrent or metastatic cervical<br \/>\n      cancer. Serious adverse reactions occurred in 39% of patients receiving<br \/>\n      KEYTRUDA. The most frequent serious adverse reactions reported included<br \/>\n      anemia (7%), fistula, hemorrhage, and infections [except urinary tract<br \/>\n      infections] (4.1% each). The most common adverse reactions (occurring in<br \/>\n      \u226520% of patients) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Findex.html&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=f765b73ba4e7069497a565882f7884d5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About the Merck Access Program for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      At Merck, we are committed to supporting accessibility to our cancer<br \/>\n      medicines. Merck provides multiple programs to help ensure that<br \/>\n      appropriate patients who are prescribed KEYTRUDA have access to our<br \/>\n      anti-PD-1 therapy. The Merck Access Program provides reimbursement<br \/>\n      support for patients receiving KEYTRUDA, including information to help<br \/>\n      with out-of-pocket costs and co-pay assistance for eligible patients.<br \/>\n      Merck also offers free product through our patient assistance program to<br \/>\n      eligible patients, primarily the uninsured, who, without our assistance,<br \/>\n      could not afford their medicine. More information is available by<br \/>\n      calling 855-257-3932 or visiting <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=www.merckaccessprogram-keytruda.com&amp;index=2&amp;md5=edbba0db41d3005417e700c39d3d610b\" rel=\"nofollow\">www.merckaccessprogram-keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck\u2019s Patient Support Program for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Merck is committed to helping provide patients and their caregivers<br \/>\n      support throughout their treatment with KEYTRUDA. The KEY+YOU Patient<br \/>\n      Support Program provides a range of resources and services. For further<br \/>\n      information and to sign up, patients and physicians may call 85-KEYTRUDA<br \/>\n      (855-398-7832) or visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.keytruda.com&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=www.keytruda.com&amp;index=3&amp;md5=6dd12f0cdfbf487e81442ee07870d9c4\" rel=\"nofollow\">www.keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola.\n    <\/p>\n<p>\n      For more information, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=24977244db11b013e873e84c947ff1b7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=b84a5456c4d9b3efacbeecd4b6c622cb\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=eca63789ae4085d6310d32dfb57292fd\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=0089a750df5f802a4e1d86b153cc1f6a\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=a8fd65307b672ba6386c77b8911d1e8e\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=dd2b2d7aed7e4073607e9db5457558fe\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=a9bbb747a35dca3d4e04fc6040b2ded9\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA<\/b><br \/>\n<br \/>\n<b>at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=11&amp;md5=0718252e602d647249248900e2b2e2d9\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><br \/>\n      <b>and Patient Information\/Medication Guide for KEYTRUDA<\/b><br \/>\n<br \/>\n<b>at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51821341&amp;newsitemid=20180612006423&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=12&amp;md5=5dc8820fd5cc7e11684bd5723600b201\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180612006423r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Michael        Close, 267-305-1211<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>KEYTRUDA Now First Anti-PD-1 Therapy Approved for Patients with Advanced Cervical Cancer and Disease Progression on or After Chemotherapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae, the company\u2019s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) \u22651] as determined by an FDA-approved test. This indication is approved under the FDA\u2019s accelerated approval regulations based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. \u201cKEYTRUDA is now the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745707","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KEYTRUDA Now First Anti-PD-1 Therapy Approved for Patients with Advanced Cervical Cancer and Disease Progression on or After Chemotherapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae, the company\u2019s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) \u22651] as determined by an FDA-approved test. This indication is approved under the FDA\u2019s accelerated approval regulations based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. \u201cKEYTRUDA is now the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\\\/\",\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-06-12T15:06:00+00:00\",\"dateModified\":\"2025-11-07T06:27:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - Merck.com","og_description":"KEYTRUDA Now First Anti-PD-1 Therapy Approved for Patients with Advanced Cervical Cancer and Disease Progression on or After Chemotherapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA\u00ae, the company\u2019s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) \u22651] as determined by an FDA-approved test. This indication is approved under the FDA\u2019s accelerated approval regulations based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. \u201cKEYTRUDA is now the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/","name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-06-12T15:06:00+00:00","dateModified":"2025-11-07T06:27:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0bccc4ba-a5b5-464f-9087-74a95893cd88","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-Previously-Treated-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer-Whose-Tumors--KXF34.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745707\/revisions"}],"predecessor-version":[{"id":3675052,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745707\/revisions\/3675052"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745707"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}